Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Healius Limited ( (AU:HLS) ) has provided an announcement.
Healius Limited reported a 5.7% increase in group revenue to $1.34 billion for FY25, with underlying EBITDA at $239.3 million and EBIT at $17.1 million, aligning with market expectations. The company has sold Lumus Imaging, resulting in a debt-free balance sheet, and is focusing on revenue diversification and cost reduction, including a $15-20 million cut in support costs. Pathology revenues grew by 6.0% despite challenges such as Tropical Cyclone Alfred, while Agilex Biolabs faced a 3.3% revenue decline due to geopolitical issues but expects recovery in FY26.
The most recent analyst rating on (AU:HLS) stock is a Sell with a A$0.71 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.
More about Healius Limited
Healius Limited operates in the healthcare industry, primarily focusing on pathology services, with additional interests in biolabs and diagnostics. The company aims to enhance its market position by expanding specialist services, such as genomics and veterinary pathology, and optimizing its operations to improve efficiency.
Average Trading Volume: 5,367,552
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$584.5M
For a thorough assessment of HLS stock, go to TipRanks’ Stock Analysis page.